Variations of serum IgG subclass levels in hepatitis C virus infection during interferon-alpha therapy

被引：5
|
作者：
Musset, L
Ghillani, P
Lunel, F
Cacoub, P
Cresta, P
Frangeul, L
Rosenheim, M
Preudhomme, JL
机构：
[1] GRP HOSP PITIE SALPETRIERE,VIROL LAB,F-75651 PARIS 13,FRANCE
[2] GRP HOSP PITIE SALPETRIERE,DEPT HEPATOGASTROENTEROL,F-75651 PARIS 13,FRANCE
[3] GRP HOSP PITIE SALPETRIERE,DEPT INTERNAL MED,F-75651 PARIS 13,FRANCE
[4] GRP HOSP PITIE SALPETRIERE,PUBL HLTH UNIT,F-75651 PARIS 13,FRANCE
[5] UNIV POITIERS HOSP,LAB IMMUNOL & IMMUNOPATHOL,CNRS URA 1172,POITIERS,FRANCE
来源：
IMMUNOLOGY LETTERS | 1997年 / 55卷 / 01期
关键词：
hepatitis C virus; IgG subclass; interferon-alpha;
D O I：
10.1016/S0165-2478(96)02681-8
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Serum IgG1 levels are selectively increased in patients with chronic hepatitis C virus (HCV) infection. In 15 patients who received interferon (IFN)-alpha therapy, serum levels of immunoglobulin classes and IgG subclasses were measured during treatment and after it was discontinued. In spite of important individual variations, mean IgG, IgG1, IgA and IgM levels decreased during therapy and tended to return to pre-treatment levels afterwards, with no detectable correlation with clinical and biological parameters. These results suggest an effect of IFN-alpha on in vivo immunoglobulin production, in HCV carriers. (C) 1997 Elsevier Science B.V.
引用
收藏
页码：41 / 45
页数：5
相关论文
共 50 条
  • [31] Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection
    Al-Muammar A.M.
    Al-Mudhaiyan T.M.
    Al Otaibi M.
    Abdo A.
    Abu El-Asrar A.M.
    International Ophthalmology, 2010, 30 (5) : 611 - 613
  • [32] Immunological response in chronic hepatitis C virus infection during interferon alpha therapy
    Panasiuk, A
    Prokopowicz, D
    Zak, J
    HEPATO-GASTROENTEROLOGY, 2004, 51 (58) : 1088 - 1092
  • [33] Enhanced Levels of Interleukin-8 Are Associated with Hepatitis B Virus Infection and Resistance to Interferon-Alpha Therapy
    Yang, Kai
    Guan, Shi-He
    Zhang, Hao
    Pan, Ying
    Wu, Yuan-Yuan
    Wang, Ai-Hua
    Sun, Bei-Bei
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2014, 15 (11): : 21286 - 21298
  • [34] Hepatitis C virus kinetics during induction and standard 3 times a week interferon-alpha therapy
    Carlsson, T
    Reichard, O
    Weiland, O
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2001, 33 (11) : 838 - 842
  • [35] Serum hepatitis C virus core protein level during interferon-alpha therapy in patients with chronic hepatitis C: relationship between biochemical and virologic responses
    Yamauchi, M
    Orito, E
    Kumada, T
    Yanagihara, O
    Kohara, M
    Mizokami, M
    HEPATOLOGY RESEARCH, 1997, 8 (03) : 189 - 197
  • [36] Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C
    Downs, AMR
    Dunnill, MGS
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2000, 25 (04) : 351 - 352
  • [37] Interferon-alpha in hepatitis C
    Koff, RS
    PHARMACOECONOMICS, 1997, 11 (05) : 491 - 491
  • [38] SERIAL ASSAY OF HEPATITIS-C VIRUS-RNA IN SERUM FOR PREDICTING RESPONSE TO INTERFERON-ALPHA THERAPY
    HINO, K
    OKUDA, M
    KONISHI, T
    ISHIKO, H
    OKITA, K
    DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (01) : 14 - 20
  • [39] INTERFERON-ALPHA THERAPY WITH AND WITHOUT INTERFERON-ALPHA PRIMING IN PATIENTS WITH CHRONIC HEPATITIS-B INFECTION
    CATTERALL, AP
    KING, R
    LAU, JYN
    DANIELS, HM
    ALEXANDER, GJM
    MURRAYLYON, IM
    WILLIAMS, R
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (05) : 777 - 782
  • [40] PRIMARY BILIARY-CIRRHOSIS INDUCED BY INTERFERON-ALPHA THERAPY FOR HEPATITIS-C VIRUS-INFECTION
    DAMICO, E
    PAROLI, M
    FRATELLI, V
    PALAZZI, C
    BARNABA, V
    CALLEA, F
    CONSOLI, G
    DIGESTIVE DISEASES AND SCIENCES, 1995, 40 (10) : 2113 - 2116
12345